Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Low energy radionuclides for permanent interstitial implantation.

B S Hilaris, J H Kim, N Tokita

    AJR. American Journal of Roentgenology
    |January 1, 1976
    PubMed
    Summary

    Iodine-125 implants show superior effectiveness compared to radon-222 and iridium-192 for cancer treatment. This study highlights iodine-125

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Preclinical studies with the photon radiosurgery system (PRS).

    International journal of radiation oncology, biology, physics·2000
    Same author

    Radiation therapy in pancreatic cancer: current practice and future trends.

    Journal of clinical gastroenterology·2000
    Same author

    Contemporary brachytherapy approaches in non-small-cell lung cancer.

    Journal of surgical oncology·1999
    Same author

    Brachytherapy in cancer of the prostate: an historical perspective.

    Seminars in surgical oncology·1997
    Same author

    Role of brachytherapy in adult soft tissue sarcomas.

    Seminars in surgical oncology·1997
    Same author

    Brachytherapy and pancreatic cancer.

    Seminars in surgical oncology·1997

    Area of Science:

    • Oncology
    • Radiotherapy
    • Medical Physics

    Background:

    • Permanent implant brachytherapy is a crucial radiotherapy technique.
    • Radon-222 and Iridium-192 have been traditionally used but present challenges.
    • Iodine-125 offers potential advantages due to its physical characteristics.

    Purpose of the Study:

    • To compare the clinical effectiveness of Iodine-125 (I-125) against Radon-222 (Rn-222) and Iridium-192 (Ir-192) in permanent implants.
    • To derive dose-response curves specifically for I-125 brachytherapy.
    • To evaluate the therapeutic ratio of I-125 in selected anatomical sites.

    Main Methods:

    • Analysis of clinical outcomes from 318 permanent implant procedures.
    • Comparative evaluation of I-125, Rn-222, and Ir-192 efficacy.
    • Determination of dose-response relationships for I-125.
    • Assessment of tumor shrinkage rates and dose delivery over time.

    Main Results:

    • Iodine-125 demonstrated a higher therapeutic ratio compared to Rn-222 and Ir-192.
    • An 80% tumor control rate is achievable with I-125 implants at a minimum tumor dose of 14,000 +/- 2,000 rads.
    • Rapid tumor shrinkage with I-125 contributes to sustained or increased dose rates, enhancing local control.
    • Tumors with longer cell cycles are particularly responsive to long half-life radionuclides like I-125.

    Conclusions:

    • Iodine-125 is a more effective radionuclide for permanent implant brachytherapy than Rn-222 and Ir-192.
    • Optimal dose distribution and initial minimum tumor dose are critical for achieving high tumor control rates with I-125.
    • The radiobiological properties of I-125, including its long half-life, favor improved local tumor control, especially for slowly proliferating tumors.

    Related Experiment Videos